Literature DB >> 27353741

The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.

Cindy Chew1, Patrick J O'Dwyer2.   

Abstract

INTRODUCTION: Accurate staging of patients with pancreatic cancer is important to avoid unnecessary operations. The aim of this study was to prospectively assess the impact of magnetic resonance (MR) imaging on preoperative staging of liver in patients with findings of resectable pancreatic cancer on computed tomography (CT).
METHODS: All patients who presented to a tertiary referral centre with pancreatic cancer between April 2012 and December 2013 were included in the study. Patients with findings of resectable disease on CT underwent further liver diffusion-weighted MR imaging, using a hepatocyte-specific contrast agent.
RESULTS: A total of 583 patients with pancreatic cancer were referred. 69 (11.8%) had resectable disease on CT. Of these 69 patients, 16 (23.2%) had liver metastases on MR imaging, while 6 (8.7%) had indeterminate lesions. Of the 16 patients with positive MR imaging findings of liver metastases, 11 died of pancreatic cancer, with a mean survival time of nine months (95% confidence interval [CI] 5.22-14.05). The mean survival time of the 47 patients with negative MR imaging findings was 16 months (95% CI 14.33-18.10; p = 0.001). Subsequently, 22 of these patients underwent surgery, and only 1 (4.5%) patient was found to have liver metastasis at surgery.
CONCLUSION: The results of the present study indicate that MR imaging improves the staging of disease in patients with resectable pancreatic cancer. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  contrast agent; diffusion-weighted imaging; hepatocyte-specific; magnetic resonance imaging of liver; pancreatic cancer

Mesh:

Year:  2016        PMID: 27353741      PMCID: PMC4971454          DOI: 10.11622/smedj.2016109

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  24 in total

1.  Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases.

Authors:  D-M Koh; D J Collins; T Wallace; I Chau; A M Riddell
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 2.  Diagnostic evaluation of solid pancreatic masses.

Authors:  Jeffrey L Tokar; Rohit Walia
Journal:  Curr Gastroenterol Rep       Date:  2013-10

Review 3.  Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis.

Authors:  Irene Floriani; Valter Torri; Eliana Rulli; Daniela Garavaglia; Anna Compagnoni; Luca Salvolini; Andrea Giovagnoni
Journal:  J Magn Reson Imaging       Date:  2010-01       Impact factor: 4.813

4.  Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure.

Authors:  David Ljungman; Kent Lundholm; Anders Hyltander
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

Review 5.  The pathology and genetics of metastatic pancreatic cancer.

Authors:  Shinichi Yachida; Christine A Iacobuzio-Donahue
Journal:  Arch Pathol Lab Med       Date:  2009-03       Impact factor: 5.534

6.  Perioperative mortality for pancreatectomy: a national perspective.

Authors:  James T McPhee; Joshua S Hill; Giles F Whalen; Maksim Zayaruzny; Demetrius E Litwin; Mary E Sullivan; Frederick A Anderson; Jennifer F Tseng
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

7.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  C J Yeo; T A Sohn; J L Cameron; R H Hruban; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

Review 8.  Imaging of pancreatic adenocarcinoma: update on staging/resectability.

Authors:  Eric P Tamm; Aparna Balachandran; Priya R Bhosale; Matthew H Katz; Jason B Fleming; Jeffrey H Lee; Gauri R Varadhachary
Journal:  Radiol Clin North Am       Date:  2012-04-06       Impact factor: 2.303

Review 9.  Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.

Authors:  Shailesh V Shrikhande; Savio George Barreto; Mahesh Goel; Supreeta Arya
Journal:  HPB (Oxford)       Date:  2012-06-14       Impact factor: 3.647

10.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation.

Authors:  M Scharitzer; A Ba-Ssalamah; H Ringl; C Kölblinger; T Grünberger; M Weber; W Schima
Journal:  Eur Radiol       Date:  2013-03-22       Impact factor: 5.315

View more
  3 in total

1.  Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.

Authors:  Linn Såve Nymo; Tor Åge Myklebust; Hanne Hamre; Bjørn Møller; Kristoffer Lassen
Journal:  BJS Open       Date:  2022-03-08

2.  A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Ji Eun Lee; Seong Hyun Kim; Soon Jin Lee; Seo-Youn Choi; Sunyoung Lee; Bo Ra Lee
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-02-28

3.  Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Hye Jin Kim; Mi-Suk Park; Jin Yong Lee; Kyunghwa Han; Yong Eun Chung; Jin-Young Choi; Myeong-Jin Kim; Chang Moo Kang
Journal:  Cancer Res Treat       Date:  2018-02-05       Impact factor: 4.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.